IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Bioventus Inc. (BVS) is a leader in active healing biological products, focusing on pain treatment, restorative therapies, and surgical solutions for orthopedic care.
Investment Thesis
Bioventus is a high-torque turnaround story in the medical biologicals sector. Following a period of aggressive acquisitions that strained its balance sheet, new management is successfully rationalizing the portfolio and focusing on its core, high-margin bone healing products. Their primary advantage is their proprietary 'active healing' platform, which uses bone-morphogenetic proteins to accelerate healing in complex fractures. This is mission-critical for orthopedic surgeons and carries significant pricing power. As the company pays down debt and harvests synergies from its acquisitions, the underlying value of its market-leading biologicals is being revealed.
Key Growth Drivers
Ortho-Biological Leadership
BVS holds a dominant position in the bone healing market, providing products that are 'spec'd in' by orthopedic surgeons for the most difficult procedures.
Operational Turnaround Catalyst
Aggressive cost-cutting and the divestiture of non-core assets are driving a rapid recovery in EBITDA margins and free cash flow.
Aging Population Demands
The increase in joint replacements and fracture treatments among the aging baby boomer population ensures a multi-decade demand for Bioventus's healing products.
Valuation & Financial Modeling
BVS trades at a deeply depressed multiple of revenue and earnings compared to its med-tech peers. If management continues to execute its deleveraging plan, we expect a massive mean-reversion in the stock's valuation.
Risk Factors & Bear Case
The primary risk is the high debt load; while improving, it remains a factor during periods of high interest rates. Additionally, competition from other biological bone-graft providers is intense.
Conclusion
Bioventus is a high-beta value play in the med-tech sector. It offers leveraged exposure to high-margin biological healing products. Rated 'Speculative Buy'.
Upcoming Catalysts
No upcoming catalysts identified.
Unlock Investment Thesis
Sign up for free access to institutional-quality research tools.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 42.9GRADE C
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
2.0%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, Bioventus Inc. (BVS) receives a "Hold" rating with a composite score of 45.9/100, ranked #475 out of 4446 stocks. Key factor scores: Quality 43/100, Value 69/100, Momentum 48/100. This is quantitative analysis only — not investment advice.
Bioventus Inc. (BVS) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Bioventus Inc. Do?
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina. Bioventus Inc. (BVS) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Kenneth M. Reali and employs approximately 1,200 people. With a market capitalization of $616M, BVS is one of the notable companies in the Healthcare sector.
Bioventus Inc. (BVS) Stock Rating — Hold (April 2026)
As of April 2026, Bioventus Inc. receives a Hold rating with a composite score of 45.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.BVS ranks #475 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Bioventus Inc. ranks #25 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
BVS Stock Price and 52-Week Range
Bioventus Inc. (BVS) currently trades at $9.10. The 52-week high for BVS is $10.13, which means the stock is currently trading -10.1% from its annual peak. The 52-week low is $5.81, putting the stock 56.6% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.
Is BVS Overvalued or Undervalued? — Valuation Analysis
Bioventus Inc. (BVS) carries a value factor score of 69/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 131.32x, compared to the Healthcare sector average of 23.63x — a premium of 456%. The price-to-book ratio stands at 2.61x, versus the sector average of 2.75x. The price-to-sales ratio is 1.08x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, BVS trades at 13.22x EV/EBITDA, versus 6.34x for the sector.
Overall, BVS's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Bioventus Inc. Profitability — ROE, Margins, and Quality Score
Bioventus Inc. (BVS) earns a quality factor score of 43/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 2.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 0.7% versus the sector average of -33.1%.
On a margin basis, Bioventus Inc. reports gross margins of 67.9%, compared to 71.5% for the sector. The operating margin is 6.9% (sector: -66.1%). Net profit margin stands at 0.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -8.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
BVS Debt, Balance Sheet, and Financial Health
Bioventus Inc. has a debt-to-equity ratio of 199.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.70x, suggesting adequate working capital coverage. Total debt on the balance sheet is $323M. Cash and equivalents stand at $42M.
BVS has a beta of 0.94, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Bioventus Inc. is 50/100, reflecting average volatility within the normal range for its sector.
Bioventus Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Bioventus Inc. reported revenue of $549M and earnings per share (EPS) of $0.34. Net income for the quarter was $5M. Gross margin was 67.9%. Operating income came in at $39M.
In FY 2025, Bioventus Inc. reported revenue of $568M and earnings per share (EPS) of $0.34. Net income for the quarter was $27M. Gross margin was 68.3%. Revenue grew -0.9% year-over-year compared to FY 2024. Operating income came in at $54M.
In Q3 2025, Bioventus Inc. reported revenue of $139M and earnings per share (EPS) of $0.05. Net income for the quarter was $4M. Gross margin was 68.0%. Revenue grew -0.2% year-over-year compared to Q3 2024. Operating income came in at $11M.
In Q2 2025, Bioventus Inc. reported revenue of $148M and earnings per share (EPS) of $0.11. Net income for the quarter was $9M. Gross margin was 69.1%. Revenue grew -2.4% year-over-year compared to Q2 2024. Operating income came in at $18M.
Over the past 8 quarters, Bioventus Inc. has demonstrated a growth trajectory, with revenue expanding from $151M to $549M. Investors analyzing BVS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
BVS Dividend Yield and Income Analysis
Bioventus Inc. (BVS) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
BVS Momentum and Technical Analysis Profile
Bioventus Inc. (BVS) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 36/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 20/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
BVS vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing BVS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BVS vs S&P 500 (SPY) comparison to assess how Bioventus Inc. stacks up against the broader market across all factor dimensions.
BVS Next Earnings Date
No upcoming earnings date has been announced for Bioventus Inc. (BVS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy BVS? — Investment Thesis Summary
Bioventus Inc. presents a balanced picture with arguments on both sides. The value score of 69/100 suggests attractive pricing relative to fundamentals.
In summary, Bioventus Inc. (BVS) earns a Hold rating with a composite score of 45.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BVS stock.
We'll email you when stocks you follow change their composite rating.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
-8.3%
Sector: 10.6%
-178% VS SCTR
Gross Margin
Core pricing power
67.9%
Sector: 71.5%
IN LINE
Operating Margin
Operating efficiency
6.9%
Sector: -66.1%
-110% VS SCTR
Net Margin
Bottom-line conversion
0.6%
Sector: -58.7%
-101% VS SCTR
Return on Equity
Equity capital efficiency
2.0%
Sector: -43.5%
-105% VS SCTR
Return on Assets
Asset base utilization
0.7%
Sector: -33.1%
-102% VS SCTR
Debt/Equity
Financial leverage load
199.0%
Sector: 32.0%
-522% VS SCTR
-5%
Price / Sales
1.1x
-35%
Bioventus Inc. exhibits a 131% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
0.7%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
67.9%
Sector: 71.5%
Operating Margin
Core business profitability
6.9%
Sector: -66.1%
Net Margin
Bottom-line profitability
0.6%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.